VEEV vs MDRX Comparison: AI Score, Valuation, Performance and Upside
Compare Veeva's life-sciences-focused cloud platform against Veradigm's smaller EHR-and-data healthcare IT business.
Use this Veeva Systems vs Veradigm comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
MDRX holds the edge across 3 of 5 key metrics in this comparison. MDRX leads on both 1-year return (+4.52%) and forward P/E quality (15.80x vs 27.41x for VEEV), a relatively favorable combination of momentum and valuation. VEEV leads on both revenue growth (17.60%) and operating margin (29.64%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for MDRX (+37.13%) than for VEEV (+4.76%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
| Metric | VEEV | MDRX |
|---|---|---|
| AI scorei | 59.0 | N/A |
| AI ranki | #190 | N/A |
| Latest closei | $266.62 | $4.86 |
| 1M returni | +9.38% | -0.82% |
| 6M returni | +42.81% | +6.81% |
| 1Y returni | -3.49% | +4.52% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | VEEV | MDRX |
|---|---|---|
| 1Y ago | $9.73K (-2.7%) started 2025-09-16 | $10.45K (+4.5%) started 2025-09-15 |
| 5Y ago | $8.74K (-12.6%) started 2021-09-16 | $3.52K (-64.8%) started 2021-09-15 |
| 10Y ago | $65.11K (+551.1%) started 2016-09-16 | $3.71K (-62.9%) started 2016-09-15 |
Hypothetical — past performance does not guarantee future results.
| Metric | VEEV | MDRX |
|---|---|---|
| Market capi | $45.45B | $516.62M |
| Trailing P/Ei | 46.10 | N/A |
| Forward P/Ei | 27.41 | 15.80 |
| Price/Salesi | N/A | 0.87 |
| EV/Revenuei | 11.02 | 0.43 |
| Analyst targeti | $294.07 | $6.50 |
| Target upsidei | +4.76% | +37.13% |
| Metric | VEEV | MDRX |
|---|---|---|
| Revenue growthi | 17.60% | 5.00% |
| Earnings growthi | 39.50% | -1.80% |
| EPS growthi | +39.50% | -1.80% |
| FCF margini | +36.37% | +2.61% |
| Operating margini | 29.64% | 16.59% |
| Profit margini | 29.34% | -49.05% |
| ROIC proxyi | 14.42% | -31.05% |
| Return on equityi | 14.42% | -31.05% |
| Dividend yieldi | N/A | 0.00% |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.92 | 0.56 |
| Debt/equityi | 2.04 | 18.59 |
| Current ratioi | 5.46 | 1.29 |
| Quick ratioi | 5.36 | 1.17 |
Over the past year, VEEV and MDRX have moved barely in opposite directions (correlation of -0.04), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | VEEV | MDRX |
|---|---|---|---|
| 1Y | Growthi | -2.65% | +4.52% |
| CAGRi | -2.66% | +4.52% | |
| Volatilityi | 42.61% | 51.11% | |
| Sharpe ratioi | 0.04 | 0.25 | |
| Sortino ratioi | 0.06 | 0.37 | |
| Max drawdowni | 50.55% | 16.00% | |
| Current drawdowni | 12.93% | 6.18% | |
| Avg drawdowni | 28.86% | 5.68% | |
| Ulcer Indexi | 32.92% | 6.97% | |
| Max daily dropi | 9.77% | 9.57% | |
| Max wkly dropi | 16.81% | 13.06% | |
| 5Y | Growthi | -12.58% | -64.78% |
| CAGRi | -2.65% | -18.84% | |
| Volatilityi | 39.46% | 48.11% | |
| Sharpe ratioi | 0.01 | -0.28 | |
| Sortino ratioi | 0.02 | -0.39 | |
| Max drawdowni | 53.54% | 83.11% | |
| Current drawdowni | 18.03% | 78.95% | |
| Avg drawdowni | 34.30% | 51.37% | |
| Ulcer Indexi | 36.53% | 57.74% | |
| Max daily dropi | 16.24% | 31.75% | |
| Max wkly dropi | 21.64% | 40.50% | |
| 10Y | Growthi | +551.09% | -62.93% |
| CAGRi | +20.61% | -9.45% | |
| Volatilityi | 38.82% | 45.88% | |
| Sharpe ratioi | 0.56 | -0.08 | |
| Sortino ratioi | 0.84 | -0.12 | |
| Max drawdowni | 55.69% | 83.11% | |
| Current drawdowni | 21.81% | 78.95% | |
| Avg drawdowni | 22.67% | 37.81% | |
| Ulcer Indexi | 28.66% | 45.87% | |
| Max daily dropi | 16.24% | 31.75% | |
| Max wkly dropi | 21.64% | 40.50% |
| Category | VEEV | MDRX |
|---|---|---|
| Company | VEEV | MDRX |
| Sector | Healthcare | N/A |
| Industry | Health Information Services | Health Information Services |
| Core business | Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. | Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.